| Literature DB >> 30307465 |
R Galot1, C Le Tourneau2, J Guigay3, L Licitra4, I Tinhofer5, A Kong6, C Caballero7, C Fortpied7, J Bogaerts7, A-S Govaerts7, D Staelens7, T Raveloarivahy7, L Rodegher7, J-F Laes8, E Saada-Bouzid3, J-P Machiels9.
Abstract
The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have very limited activity in unselected SCCHN, and the current treatment strategy is still based on tumor location and disease stage and not on tumor biology. Trying to select upfront the patients who will benefit from a specific treatment might be a way to improve patients' outcome. With the objective of optimizing the activity of targeted therapies and immunotherapy, we have designed an umbrella biomarker-driven study dedicated to recurrent and/or metastatic SCCHN patients (EORTC-1559-HNCG, NCT03088059). In this article, we review not only the different trial designs for biomarker-driven studies with their respective advantages and opportunities but also the potential pitfalls that led to the design of the EORTC-1559-HNCG protocol. We also discuss the scientific and logistic challenges of biomarker-driven trials.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30307465 DOI： 10.1093/annonc/mdy452
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976